Aligos Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Aligos Therapeutics, Inc. (ALGS) reported Increase (Decrease) in Contract with Customer, Liability of -$569.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-11-06
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was -$671.00K.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $605.00K.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$503.00K.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was -$634.00K.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $524.00K.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$4.36M, a 136.33% decline from fiscal 2020.
- Aligos Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $12.00M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$671.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$66.00K derived: sum of 2 quarters · filed 2024-11-06 | -$569.00K 10-Q · filed 2024-11-06 | -$1.20M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | $605.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $102.00K 10-Q · filed 2024-08-06 | -$532.00K derived: sum of 3 quarters · filed 2024-08-06 | -$1.61M derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-03-31 | -$503.00K 10-Q · filed 2024-05-07 | -$1.14M derived: sum of 2 quarters · filed 2024-05-07 | -$2.22M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-12-31 | -$634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$1.72M derived: sum of 2 quarters · filed 2024-11-06 | $524.00K 10-K · filed 2024-03-12 | |
| 2023-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.16M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.24M 10-Q · filed 2024-08-06 | |||
| 2022-09-30 | -$4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$7.80M derived: sum of 2 quarters · filed 2022-11-02 | $4.64M 10-Q · filed 2022-11-02 | $4.27M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | -$3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $8.74M 10-Q · filed 2022-08-04 | $8.38M derived: sum of 3 quarters · filed 2022-08-04 | $6.84M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $12.44M 10-Q · filed 2022-05-04 | $12.07M derived: sum of 2 quarters · filed 2022-05-04 | $10.53M derived: sum of 3 quarters · filed 2022-11-02 | $8.99M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | -$367.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$1.90M derived: sum of 2 quarters · filed 2022-11-02 | -$3.45M derived: sum of 3 quarters · filed 2022-11-02 | -$4.36M 10-K · filed 2022-03-10 |
| 2021-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$3.08M derived: sum of 2 quarters · filed 2022-11-02 | -$3.99M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$2.46M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$910.00K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $12.00M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |